Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibeshih Belachew

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
NPJ Digital Medicine|March 29, 2023
Evolving regulatory perspectives on digital health technologies for medicinal product developmentSeya Colloud, Thomas Metcalfe, Scott Askin, et al.
Stroke|April 3, 2010
Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular diseaseRaf Brouns, Vincent Thijs, François Eyskens, et al.
BMJ Neurology Open|June 20, 2022
Chronic lesion activity and disability progression in secondary progressive multiple sclerosisVanessa Beynon, Ilena C George, Colm Elliott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 14, 2021
A smartphone sensor-based digital outcome assessment of multiple sclerosisXavier Montalban, Jennifer Graves, Luciana Midaglia, et al.
Cell|February 3, 2009
Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulinCatherine Creppe, Lina Malinouskaya, Marie-Laure Volvert, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritisOrhan Aktas, Focke Ziemssen, Tjalf Ziemssen, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Brain Communications|September 24, 2021
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions ariseColm Elliott, Parya Momayyezsiahkal, Douglas L Arnold, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
NPJ Digital Medicine|March 29, 2023
Evolving regulatory perspectives on digital health technologies for medicinal product developmentSeya Colloud, Thomas Metcalfe, Scott Askin, et al.
Stroke|April 3, 2010
Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular diseaseRaf Brouns, Vincent Thijs, François Eyskens, et al.
BMJ Neurology Open|June 20, 2022
Chronic lesion activity and disability progression in secondary progressive multiple sclerosisVanessa Beynon, Ilena C George, Colm Elliott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 14, 2021
A smartphone sensor-based digital outcome assessment of multiple sclerosisXavier Montalban, Jennifer Graves, Luciana Midaglia, et al.
Cell|February 3, 2009
Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulinCatherine Creppe, Lina Malinouskaya, Marie-Laure Volvert, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritisOrhan Aktas, Focke Ziemssen, Tjalf Ziemssen, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Brain Communications|September 24, 2021
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions ariseColm Elliott, Parya Momayyezsiahkal, Douglas L Arnold, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Pageof 9